Skip to content
Aperlena

Romania - Antineoplastic drugs - Oncology medicines

Original România - Antineoplazice - Medicamente Oncologice

Open Contract notice 5 days left
Watch this tender

Deadline 21 Sep. If it moves, an email when the register sees it. A correction: the same email. Log in

  1. Published
  2. Today
  3. Deadline open for 35 days
  4. Awarded pending

The Aperlena Verdict

Open race

No supplier dominates: 10 different companies have won the last 11 comparable contracts from this buyer over 5 years. This is a genuinely open race.

-0.4%
Expected final price vs the published estimate

Based on 11 comparable awards by this buyer in this sector over 5 years. Every verdict is recorded before the outcome and graded against the award notice. How we score ourselves.

Summary

Machine-generated summary

A Romanian contracting authority is procuring oncology medicines, including antineoplastic agents such as aflibercept, atezolizumab, bevacizumab, bleomycin, cabazitaxel, carboplatin, cemiplimab, cetuximab and cisplatin, in specified pack sizes. After conclusion of the framework agreement, subsequent contracts will be awarded according to needs and available funds. Minimum and maximum quantities for the framework and for each lot are listed in Annex 1 of the tender documentation. The estimated value of the largest subsequent contract is given in the specifications and in the Lots section. Clarification requests must be submitted 20 days before the bid deadline, and answers will be provided 11 days before that deadline. Framework agreement procedure.

Description

In urma incheierii acordului cadru, autoritatea contractanta va incheia contracte subsecvente, in functie de necesitati si fonduri disponibile. Cantitatile minime si maxime care ar putea fi solicitate pe durata intregului acord cadru, precum si cantitatile minime si maxime care ar putea face obiectul unui singur contract subsecvent sunt specificate in anexa 1 a caietului de sarcini.Valorile estimate a celui mai mare contract subsecvent sunt specificate in caietul de sarcini si sectiunea Loturi, Informatii suplimentare. Cantitatile minime si maxime specificate la fiecare lot, reprezinta cantitatile acordului cadru. Autoritatea contractanta va raspunde in mod clar si complet tuturor solicitarilor de clarificare/informatiilor suplimentare in a 11 - a zi inainte de termenul limita de depunere a ofertelor. Numarul de zile pana la care se pot solicita clarificari, inainte de data limita de depunere a ofertelor este de 20. Aflibercept conc. pt. sol. perf. 25mg/ml - flacon 10 ml x 8 ml concentrat AC. cant. min. 2 - max. 48; Aflibercept conc. pt. sol. perf. 25mg/ml - flacon 5 ml x 4 ml concentrat AC. cant. min. 2 - max. 48; Atezolizumab conc. pt. sol. perf. 1200mg/20ml AC. cant. min. 6 - max. 144; Bevacizumabum conc. pt. sol. perf. 25mg/ml - flacon 16ml AC. cant. min. 10 - max. 240; Bevacizumabum conc. pt. sol. perf. 25mg/ml - flacon 4ml AC. cant. min. 10 - max. 240; bleomycinum sulfas pulb. pt. sol. inj./perf. 15000UI AC. cant. min. 2 - max. 48; Cabazitaxelum conc. pt. sol. perf. 20mg/ml - flacon 3 ml conc. AC. cant. min. 1 - max. 24; Calcii Folinas. sol. inj./perf. 10mg/ml - flacon 10ml AC. cant. min. 12 - max. 288; Carboplatinum conc. pt. sol. perf. 10mg/ml - flacon 45ml AC. cant. min. 10 - max. 240; Carboplatinum conc. pt. sol. perf. 10mg/ml - flacon 15ml AC. cant. min. 10 - max. 240; Cemiplimabum conc. pt. sol. perf. 350mg AC. cant. min. 1 - max. 24; Cetuximabum sol. perf. 5mg/ml flacon 20ml AC. cant. min. 8 - max. 192; Cisplatinum conc. pt. sol. perf. 1mg/ml flacon 50ml AC. cant. min. 10 - max. 240; Cyclophosphamidum conc. pt. sol. perf./ inj. 200mg AC. cant. min. 12 - max. 288; Dacarbazinum pulb. pt. sol. inj./perf. 200mg AC. cant. min. 10 - max. 240; Docetaxelum conc. pt. sol. perf. 80mg/4ml AC. cant. min. 6 - max. 144; Docetaxelum conc. pt. sol. perf. 20mg/1ml AC. cant. min. 4 - max. 96; Doxorubicinum conc. pt. sol. perf. 2mg/ml flacon 25ml AC. cant. min. 6 - max. 144; Doxorubicinum pegylated liposomal conc. pt. dispersie 2mg/ml flacon 10ml AC. cant. min. 2 - max. 48; Durvalumabum conc. pt. sol. perf. 50mg/ml - flacon 10ml AC. cant. min. 2 - max. 48; Epirubicinum sol. inj./perf. 2mg/ml - flacon 25ml AC. cant. min. 10 - max. 240; Epirubicinum sol. inj./perf. 2mg/ml - flacon 50ml AC. cant. min. 8 - max. 192; Fluorouracilum conc. pt. sol. perf. 50mg/ml - flacon 20ml AC. cant. min. 20 - max. 480; Gemcitabinum conc. pt. sol. perf./ inj. 100mg/ml flacon 10ml AC. cant. min. 15 - max. 360; Gemcitabinum conc. pt. sol. perf./ inj. 100mg/ml flacon 2ml AC. cant. min. 10 - max. 240; Ifosfamidum pulb. pt. sol. perf. 1gr/30ml AC. cant. min. 4 - max. 96; Irinotecanum conc. pt. sol. perf. 20mg/ml - flacon 5ml AC. cant. min. 10 - max. 240; Irinotecanum conc. pt. disperie 4.3 mg/ml AC. cant. min. 2 - max. 48; Nivolumabum conc. pt. sol. perf. 10mg/ml - flacon 4 ml AC. cant. min. 10- max. 240; Nivolumabum conc. pt. sol. perf. 10mg/ml - flacon 10 ml AC. cant. min. 20- max. 480; Oxaliplatinum conc. pt. sol. perf. 5mg/ml - flacon 10 ml AC. cant. min. 10 - max. 240; Oxaliplatinum conc. pt. sol. perf. 5mg/ml - flacon 20 ml AC. cant. min. 14 - max. 336; Paclitaxelum conc. pt. sol. perf. 6mg/ml - flacon 16,67 ml AC. cant. min. 10 - max. 240; Paclitaxelum conc. pt. sol. perf. 6mg/ml - flacon 50 ml AC. cant. min. 10 - max. 240; Panitumumabum conc. pt. sol. perf. 20mg/ml - flacon 5 ml AC. cant. min. 1 - max. 24; Pembrolizumabum conc. pt. sol. perf. 25mg/ml - flacon 4 ml AC. cant. min. 28 - max. 672; Pemetrexedum conc. pt. sol. perf. 25mg/ml - flacon 20 ml AC. cant. min. 10 - max. 240; Ramucirumabum conc. pt. sol. perf. 10mg/ml AC. cant. min. 10 - max. 240; Topotecamum conc. pt. sol. perf. 1mg/ml - flacon 2ml AC. cant. min. 8 - max. 192; Trastuzumabum pulb. pt. conc. pt. sol. perf. 420mg AC. cant. min. 1 - max. 24; Trastuzumabum pulb. pt. conc. pt. sol. perf. 150mg AC. cant. min. 1 - max. 24; Trastuzumabum pulb. pt. conc. pt. sol. perf. 60mg AC. cant. min. 1 - max. 24; Trastuzumabum emtansin pulb. pt. conc. pt. sol. perf. 100mg AC. cant. min. 1 - max. 24; Trastuzumabum emtansin pulb. pt. conc. pt. sol. perf. 160mg AC. cant. min. 1 - max. 24; Tremelimumabum conc. pt. sol. perf. 20mg/ml AC. cant. min. 1 - max. 24; Vaccin BCG pulb. + solv. pt. susp. intravezicala AC. cant. min. 10 - max. 240; Transtuzumabum Deruxtecanum pulb. pt. conc. pt. sol. perf. 100mg AC. cant. min. 6 - max. 144; Avelumabum conc. pt. sol. perf. 20mg/ml AC. cant. min. 8 - max. 192

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 3 weeks ago

More from this buyer

Full buyer profile

9 open tenders right now

Who usually wins this buyer's contracts in this sector

Based on 11 awards with a linked company profile over the last 5 years.

What this buyer has paid before

Based on 5 comparable contracts this buyer awarded in this sector over the last 4 years.

€107,522
Lower quartile
€142,923
Median award
€384,710
Upper quartile

This tender is estimated 3155.7% above that median

Most recent awards

Award values as published by the official sources. Use them as a guide, not a rule: scope, lots and duration differ between contracts.

Similar tenders

Market context

Avg. open tender · Medical equipment & pharmaceuticals
€9,278,779
11,440 open across Europe right now 50% below sector average
Buyer track record on Aperlena
37 notices tracked · 17 awarded
€1,042,623 in awarded contracts

Never miss a tender like this

260 new notices in Medical equipment & pharmaceuticals in Romania in the last 7 days. Get an email when new ones appear. Free.

Set up my alert

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
/
Jump to the search box
?
Show these shortcuts
Esc
Close